Kasugai H, Ishiyama J, Imai I, Fukuma E, Miyajima N, Kano N, Yamakawa T, Goto S, Kera J, Takeuchi S
Dept. of Surgery, Teikyo University Mizonokuchi Hospital.
Gan To Kagaku Ryoho. 1995 Sep;22(11):1690-3.
A case of far advanced gastric cancer with multiple liver metastasis (H3) was treated with transarterial intermittent chemotherapy (5-FU: 250 mg/week, Farmorubicin: 10 mg/4 weeks, MMC: 4 mg/2 weeks) and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans. The CT examination and endoscopy showed regression of the tumor and the patient was discharged from the hospital. LPSp was given at the concentration of 0.1 microgram initially, and the dose was gradually increased. Finally, the dose of LPSp was increased up to 70 micrograms. No serious side effect except fever was observed. The serum TNF-alpha levels were elevated and, histologically, CD 8(+) lymphocyte dominantly infiltrated around the tumor. These findings clearly indicated the immunological anticancer effect of LPSp. Intradermal administration of LPSp is a promising new adjuvant therapy to improve QOL without serious side effect.
一例伴有多发肝转移(H3期)的进展期胃癌患者接受了经动脉间歇性化疗(5-氟尿嘧啶:250毫克/周,表柔比星:10毫克/4周,丝裂霉素:4毫克/2周)以及皮内注射从成团泛菌中提取的低分子脂多糖(LPSp)。CT检查和内镜检查显示肿瘤消退,患者出院。最初给予LPSp的浓度为0.1微克,剂量逐渐增加。最终,LPSp的剂量增加至70微克。除发热外未观察到严重副作用。血清肿瘤坏死因子-α水平升高,组织学检查显示肿瘤周围主要是CD8(+)淋巴细胞浸润。这些发现清楚地表明了LPSp的免疫抗癌作用。皮内注射LPSp是一种有前景的新辅助治疗方法,可改善生活质量且无严重副作用。